Literature DB >> 29543916

Correction: Molecular Subtypes in Head and Neck Cancer Exhibit Distinct Patterns of Chromosomal Gain and Loss of Canonical Cancer Genes.

Vonn Walter, Xiaoying Yin, Matthew D Wilkerson, Christopher R Cabanski, Ni Zhao, Ying Du, Mei Kim Ang, Michele C Hayward, Ashley H Salazar, Katherine A Hoadley, Karen Fritchie, Charles J Sailey, Mark C Weissler, William W Shockley, Adam M Zanation, Trevor Hackman, Leigh B Thorne, William D Funkhouser, Kenneth L Muldrew, Andrew F Olshan, Scott H Randell, Fred A Wright, Carol G Shores, D Neil Hayes.   

Abstract

[This corrects the article DOI: 10.1371/journal.pone.0056823.].

Entities:  

Year:  2018        PMID: 29543916      PMCID: PMC5854434          DOI: 10.1371/journal.pone.0194674

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


In S7 Fig, the names of cell lines are incorrectly matched to the underlying data. Please see the corrected S7 Fig here.

Copy number plots from the Cancer Cell Line Encyclopedia data.

Copy number plots show that genomic events detected in the UNC HNSCC cohort can also be found in the HNSCC cell lines from the Cancer Cell Line Encyclopedia. A. Amplifications in chromosome 3q are seen in all predicted subtypes, and the predicted classical subtype exhibits focal amplification of the region containing SOX2. B. HSC2 (predicted basal) exhibits focal amplification of EGFR, while KYSE510 (predicted atypical) does not. C. Both BIRC31 (predicted mesenchymal) and KYSE180 (predicted classical) exhibit focal deletion of CDKN2A. D. Both SCC15 (predicted mesenchymal) and PECAPJ34 (predicted basal) exhibit focal amplification of CCND1. Note that gains of 11q22 are also seen for SCC15. (TIF) Click here for additional data file.
  1 in total

1.  Molecular subtypes in head and neck cancer exhibit distinct patterns of chromosomal gain and loss of canonical cancer genes.

Authors:  Vonn Walter; Xiaoying Yin; Matthew D Wilkerson; Christopher R Cabanski; Ni Zhao; Ying Du; Mei Kim Ang; Michele C Hayward; Ashley H Salazar; Katherine A Hoadley; Karen Fritchie; Charles J Sailey; Charles G Sailey; Mark C Weissler; William W Shockley; Adam M Zanation; Trevor Hackman; Leigh B Thorne; William D Funkhouser; Kenneth L Muldrew; Andrew F Olshan; Scott H Randell; Fred A Wright; Carol G Shores; D Neil Hayes
Journal:  PLoS One       Date:  2013-02-22       Impact factor: 3.240

  1 in total
  1 in total

1.  Comparing PI3K/Akt Inhibitors Used in Ovarian Cancer Treatment.

Authors:  Yi-Hui Wu; Yu-Fang Huang; Chien-Chin Chen; Chia-Yen Huang; Cheng-Yang Chou
Journal:  Front Pharmacol       Date:  2020-03-03       Impact factor: 5.810

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.